EE05232B1 - Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm - Google Patents

Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm

Info

Publication number
EE05232B1
EE05232B1 EEP200100254A EEP200100254A EE05232B1 EE 05232 B1 EE05232 B1 EE 05232B1 EE P200100254 A EEP200100254 A EE P200100254A EE P200100254 A EEP200100254 A EE P200100254A EE 05232 B1 EE05232 B1 EE 05232B1
Authority
EE
Estonia
Prior art keywords
preparation
dosage form
controlled release
unit dosage
form containing
Prior art date
Application number
EEP200100254A
Other languages
English (en)
Estonian (et)
Inventor
Gren Torkel
Ringberg Anders
Wikberg Martin
J. Wald Randy
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE200100254A publication Critical patent/EE200100254A/xx
Publication of EE05232B1 publication Critical patent/EE05232B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200100254A 1998-11-11 1999-11-11 Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm EE05232B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Publications (2)

Publication Number Publication Date
EE200100254A EE200100254A (et) 2002-12-16
EE05232B1 true EE05232B1 (et) 2009-12-15

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100254A EE05232B1 (et) 1998-11-11 1999-11-11 Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm

Country Status (40)

Country Link
US (1) US6911217B1 (xx)
EP (1) EP1128819B1 (xx)
JP (1) JP3616011B2 (xx)
KR (1) KR100467384B1 (xx)
CN (1) CN1169522C (xx)
AP (1) AP1323A (xx)
AR (1) AR027815A1 (xx)
AT (1) ATE247458T1 (xx)
AU (1) AU762410B2 (xx)
BG (1) BG65149B1 (xx)
BR (1) BRPI9915142B8 (xx)
CA (1) CA2350061C (xx)
CZ (1) CZ299582B6 (xx)
DE (1) DE69910604T2 (xx)
DK (1) DK1128819T3 (xx)
EA (1) EA005074B1 (xx)
EE (1) EE05232B1 (xx)
ES (1) ES2204193T3 (xx)
GE (1) GEP20022833B (xx)
HK (1) HK1040917B (xx)
HR (1) HRP20010333B1 (xx)
HU (1) HU226582B1 (xx)
ID (1) ID30039A (xx)
IL (1) IL142809A0 (xx)
IS (1) IS2370B (xx)
MA (1) MA25325A1 (xx)
MY (1) MY122195A (xx)
NO (1) NO331399B1 (xx)
NZ (1) NZ511430A (xx)
OA (1) OA11673A (xx)
PL (1) PL195780B1 (xx)
PT (1) PT1128819E (xx)
RS (1) RS49891B (xx)
SE (1) SE9803871D0 (xx)
SI (1) SI1128819T1 (xx)
SK (1) SK284758B6 (xx)
TW (2) TWI222879B (xx)
UA (1) UA57165C2 (xx)
WO (1) WO2000027364A1 (xx)
ZA (1) ZA200103575B (xx)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
EE05191B1 (et) * 1999-11-11 2009-08-17 Pharmacia Ab Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
EP1536780A1 (en) * 2002-08-28 2005-06-08 Pharmacia Corporation Oral liquid tolterodine composition
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
AU2004206110A1 (en) * 2003-01-22 2004-08-05 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
CA2537103C (en) 2003-11-04 2010-01-19 Shire Laboratories, Inc. Once daily dosage forms of trospium
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
EP1836156A1 (en) * 2005-01-10 2007-09-26 Teva Gyogyszergyar Reszvenytarsasag Substantially pure tolterodine tartrate and process for preparing thereof
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP2997953B1 (en) 2006-01-18 2018-12-26 Intec Pharma Ltd. Delivery device for oral intake of an agent
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
MX2008010877A (es) * 2006-02-24 2008-11-25 Teva Pharma Tabletas de liberacion prolongada de succinato de metroprolol y metodos para su preparacion.
BRPI0708848A2 (pt) * 2006-03-21 2011-06-21 Teva Pharma formulação de liberação controlada de tolterodina
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
EA018036B1 (ru) 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
DK3342405T3 (da) 2007-04-25 2019-11-11 Opko Ireland Global Holdings Ltd Kontrolleret frigivelse af 25-hydroxyvitamin d
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CN101801350A (zh) * 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 抗滥用药物、使用方法和制备方法
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
US20090311317A1 (en) * 2008-05-14 2009-12-17 Capricorn Pharma Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
AU2010277207B2 (en) * 2009-07-31 2014-06-26 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
CA2793485A1 (en) 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2013037708A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
US20140242158A1 (en) * 2011-09-30 2014-08-28 Astellas Pharma, Inc. Granular Pharmaceutical Composition
MX2015000541A (es) 2012-07-12 2015-05-11 Ferring Bv Formulaciones de diclofenaco.
JP2015529255A (ja) * 2012-09-20 2015-10-05 オーエイチアール ファーマ， エルエルシーＯｈｒ Ｐｈａｒｍａ， Ｌｌｃ 治療薬の持続放出のための多層の生体分解可能なマイクロ粒子
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
EP2968579B1 (en) * 2013-03-13 2020-04-15 Intervet International B.V. Stable bioactive substances and methods of making
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2936748C (en) * 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2017146053A1 (ja) * 2016-02-23 2017-08-31 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
HK1040917A1 (en) 2002-06-28
IS5936A (is) 2001-05-09
ZA200103575B (en) 2002-05-03
ATE247458T1 (de) 2003-09-15
DK1128819T3 (da) 2003-12-01
MY122195A (en) 2006-03-31
HRP20010333B1 (en) 2004-10-31
TWI267385B (en) 2006-12-01
NZ511430A (en) 2003-05-30
SI1128819T1 (en) 2003-12-31
SK284758B6 (sk) 2005-11-03
MA25325A1 (fr) 2001-12-31
PL195780B1 (pl) 2007-10-31
BRPI9915142B8 (pt) 2021-05-25
BRPI9915142B1 (pt) 2015-08-25
BG105582A (en) 2001-12-29
HU226582B1 (en) 2009-04-28
UA57165C2 (uk) 2003-06-16
CZ299582B6 (cs) 2008-09-10
NO20012314D0 (no) 2001-05-10
JP2003517446A (ja) 2003-05-27
AU762410B2 (en) 2003-06-26
HK1040917B (zh) 2005-05-27
CA2350061A1 (en) 2000-05-18
SE9803871D0 (sv) 1998-11-11
NO331399B1 (no) 2011-12-19
CZ20011627A3 (cs) 2001-10-17
CA2350061C (en) 2005-05-17
ID30039A (id) 2001-11-01
EE200100254A (et) 2002-12-16
US6911217B1 (en) 2005-06-28
AU1436600A (en) 2000-05-29
AR027815A1 (es) 2003-04-16
EA005074B1 (ru) 2004-10-28
NO20012314L (no) 2001-07-09
TWI222879B (en) 2004-11-01
EP1128819B1 (en) 2003-08-20
OA11673A (en) 2005-01-12
HRP20010333A2 (en) 2003-04-30
IL142809A0 (en) 2002-03-10
PL348612A1 (en) 2002-06-03
KR100467384B1 (ko) 2005-01-24
HUP0105038A2 (en) 2002-06-29
PT1128819E (pt) 2003-12-31
GEP20022833B (en) 2002-11-25
BR9915142A (pt) 2001-08-07
AP1323A (en) 2004-11-05
CN1326339A (zh) 2001-12-12
WO2000027364A1 (en) 2000-05-18
DE69910604T2 (de) 2004-06-24
YU33101A (sh) 2003-10-31
CN1169522C (zh) 2004-10-06
HUP0105038A3 (en) 2006-07-28
AP2001002166A0 (en) 2001-06-30
KR20010075695A (ko) 2001-08-09
RS49891B (sr) 2008-08-07
EP1128819A1 (en) 2001-09-05
JP3616011B2 (ja) 2005-02-02
IS2370B (is) 2008-06-15
EA200100538A1 (ru) 2001-10-22
BG65149B1 (bg) 2007-04-30
DE69910604D1 (de) 2003-09-25
SK6252001A3 (en) 2002-01-07
ES2204193T3 (es) 2004-04-16

Similar Documents

Publication Publication Date Title
EE05232B1 (et) Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE04996B1 (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
HUP0103633A2 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
EE03613B1 (et) Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0300894A3 (en) Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0103567A3 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
EP1331517A4 (en) POSITIVE LIGHT-SENSITIVE RESIN COMPOSITION, PROCESS FOR THEIR MANUFACTURE AND SEMICONDUCTOR COMPONENTS
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
FR2791059B1 (fr) Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HK1039122A1 (zh) 取代的6-苄基-4-氧代嘧啶，其製備方法以及含該化合物的藥物組合物
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231